Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 68Terminated 11Recruiting 10No longer available 4Active not recruiting 4Unknown 3Not yet recruiting 3Withdrawn 2Suspended 1Available 1Approved for marketing 1

Sponsor Class

OTHER 32INDUSTRY 3OTHER_GOV 2NETWORK 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3

Conditions

Neoplasms 183Breast Neoplasms 174Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 105Stomach Neoplasms 81Pancreatic Neoplasms 79Lung Neoplasms 79Prostatic Neoplasms 77Melanoma 68Recurrence 67Neoplasm Metastasis 67Leukemia, Myeloid, Acute 66Multiple Myeloma 65Ovarian Neoplasms 62Carcinoma, Hepatocellular 62Lymphoma 61Advanced Solid Tumor 61Advanced Solid Tumors 56Solid Tumor 50Lymphoma, Non-Hodgkin 49Uterine Cervical Neoplasms 48Glioblastoma 44Lymphoma, B-Cell 40Leukemia 39Colonic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Head and Neck Neoplasms 33Esophageal Neoplasms 32Urinary Bladder Neoplasms 30Sarcoma 30

Interventions

famitinib 1anlotinib 1TH 302 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Gastrointestinal Stromal Tumors × Clear all
NCT04106024 2019-09-26

Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial

Cttq

Phase 2 Unknown
60 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02336724 2018-04-17

A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
88 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01381822 2014-04-21

TH-CR-410

Threshold Pharmaceuticals

Phase 1 Unknown
58 enrolled
GastrointestinalSarcoma

Neuroectodermal Tumors, Primitive, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡